Oramed Pharmaceuticals Parties Intend For JV To Initiate Phase 3 Oral Insulin Trial In The U.S.; Oramed Will Be Entitled To Receive A 3% Royalty On Gross Revenues Of JV Generated From Oramed Related Assets
Portfolio Pulse from Charles Gross
Oramed Pharmaceuticals and its partners plan to initiate a Phase 3 trial in the U.S. for oral insulin. Oramed will receive a 3% royalty on gross revenues generated from its related assets by the joint venture.

January 23, 2024 | 9:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oramed Pharmaceuticals is moving forward with a Phase 3 trial for oral insulin in the U.S. and will receive a 3% royalty on gross revenues from the joint venture.
The initiation of a Phase 3 trial is a significant milestone for Oramed Pharmaceuticals, indicating progress in its product pipeline. The agreement to receive a 3% royalty on gross revenues from the joint venture's use of Oramed's assets is likely to be viewed positively by investors, as it provides a future revenue stream contingent on the success of the trial and subsequent commercialization. This news is directly related to Oramed's core business and future earnings potential, hence the high relevance and importance. The positive score reflects the expectation that this news will likely be well-received by the market in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100